Zosano Pharma Corporation announced that the last subject has been treated in the Company’s registration-enabling, pivotal efficacy trial (the Zotrip trial), of M207 for the treatment of migraine. The Zotrip pivotal efficacy trial is a multicenter, double-blind, randomized, placebo-controlled trial comparing three doses of M207 (1.0 mg, 1.9mg, and 3.8mg) to placebo for the treatment of a single migraine attack. Subjects were enrolled in the Zotrip trial at 36 centers across the United States. Subjects recruited into the Zotrip trial had a history of at least one year of migraine episodes with or without aura. Upon recruitment, the subjects entered a run-in period that ensured they met the key eligibility criteria of 2-8 migraine attacks per month, which was documented using an electronic diary. Successfully screened subjects were then randomized into the treatment/dosing period in which they had 8 weeks to confirm and receive blinded treatment for a single migraine attack. The co-primary endpoints of this study are: proportion of subjects with pain freedom at 2 hours post-dosing, and proportion of subjects with freedom from their most bothersome symptom at 2 hours post-dosing. These symptoms include photophobia, phonophobia or nausea, pre-specified by each subject.